The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
Open accessAbstract
Diffuse large B cell lymphomas (DLBCLs) arise from proliferating B cells transiting different stages of the germinal center reaction. In activated B cell DLBCLs (ABC-DLBCLs), a class of DLBCLs that respond poorly to current therapies, chromosomal translocations and amplification lead to constitutive expression of the B cell lymphoma 6 (BCL6) oncogene. The role of BCL6 in maintaining these lymphomas has not been investigated. Here, we designed small-molecule inhibitors that display higher affinity for BCL6 than its endogenous corepressor ligands to evaluate their therapeutic efficacy for targeting ABC-DLBCL. We used an in silico drug design functional-group mapping approach called SILCS to create a specific BCL6 inhibitor called FX1 that has 10-fold greater potency than endogenous corepressors and binds an essential region of the BCL6 lateral groove. FX1 disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, and mimicked the phenotype of mice engineered to express BCL6 with corepressor binding site mutations. Low doses of FX1 induced regression of established tumors in mice bearing DLBCL xenografts. Furthermore, FX1 suppressed ABC-DLBCL cells in vitro and in vivo, as well as primary human ABC-DLBCL specimens ex vivo. These findings indicate that ABC-DLBCL is a BCL6-dependent disease that can be targeted by rationally designed inhibitors that exceed the binding affinity of natural BCL6 ligands.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several peptide and small molecule inhibitors targeting BCL6 have shown efficacy in vivo, but only at high concentrations, which has limited their translation into clinical therapeutic agents13,14.”
From Small-molecule-induced polymerization triggers degradation of BCL6 (2020) · cites this paper as [14]
In the citing paper
“BCL6 is a promising drug target for non-Hodgkin lymphomas including diffuse large B cell lymphoma (DLBCL)13,14 and follicular lymphoma15.”
From Small-molecule-induced polymerization triggers degradation of BCL6 (2020) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Hans, C. P. (2003) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 4,270
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 4,196
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 2,002
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B. A., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,353
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,205
Protein-binding assays in biological liquids using microscale thermophoresis
Wienken, C. J., Baaske, P., Rothbauer, U., Braun, D., & Duhr, S. (2010) · Nature Communications · doi:10.1038/ncomms1093 · Cited by 1,145
Wright, G. W., Tan, B. K., Rosenwald, A., Hurt, E. H., Wiestner, A. U., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,055
Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K. K., Klasa, R. J., Macpherson, N. A., O'Reilly, S., Spinelli, J. J., Sutherland, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.137 · Cited by 985
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–188 of 188
Ribosome changes reprogram translation for chemosurvival in G0 leukemic cells
Datta, C., Truesdell, S. S., Wu, K. Q., Bukhari, S. I. A., Ngue, H., Buchanan, B., Tonquèze, O. L., Lee, S., Kollu, S., Granovetter, M. A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo1304 · Cited by 15
Cai, Y., Poli, A. N. R., Vadrevu, S. K., Gyampoh, K., Hart, C., Ross, B. N., Fair, M., Xue, F., Salvino, J. M., & Montaner, L. J. (2021) · European Journal of Immunology · doi:10.1002/eji.202049150 · Cited by 12
Self-citationRitter, A., Safdar, B. K., Jasmer, B., Kreis, N., Friemel, A., Roth, S., Solbach, C., Louwen, F., & Yuan, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218393 · Cited by 11
Tsuzuki, S., Yasuda, T., Goto, H., Maeda, N., Akahane, K., Inukai, T., Yamamoto, H., Karnan, S., Ota, A., Hyodo, T., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280879 · Cited by 11
Cai, Y., Watkins, M., Xue, F., Ai, Y., Cheng, H., Midkiff, C. C., Wang, X., Alvarez, X. A., Poli, A. N. R., Salvino, J. M., et al. (2019) · Journal of Medical Primatology · doi:10.1111/jmp.12438 · Cited by 11
Self-citationImmune targeted therapy for diffuse large B cell lymphoma
Zheng, Y., Si, J., Tian, Y., Ding, S., & Tian, C. (2021) · Blood Science · doi:10.1097/bs9.0000000000000095 · Cited by 10
Marullo, R., Rutherford, S. C., Leonard, J. P., & Cerchietti, L. C. A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1207839 · Cited by 9
Self-citationChen, D., Zhao, H.-M., Deng, X., Li, S.-P., Zhou, M.-H., Wu, Y., Tong, Y., Yu, R., & Pang, Q. (2024) · Experimental Lung Research · doi:10.1080/01902148.2024.2320665 · Cited by 8
Yu, X., Liao, X., Zhang, J., Wang, H., Li, X., Lu, J., Zhou, H., Wu, M., Jin, Y., Zhu, X. J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01237 · Cited by 9
Jin, Y., Liao, X., Zhang, J., Duan, H., Xu, R., Luo, X., Yu, X., Li, B., Wang, J., Li, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01159 · Cited by 9
Pierrat, O. A., Liu, M., Collie, G. W., Shetty, K. N., Rodrigues, M. J., Bihan, Y. L., Gunnell, E. A., McAndrew, C., Stubbs, M., Rowlands, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23264-z · Cited by 8
Karimi, S., Shahabi, F., Mubarak, S. M. H., Arjmandi, H., Hashemi, Z. S., Pourzardosht, N., Zakeri, A., Mahboobi, M., Jahangiri, A., Rahbar, M. R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25587-3 · Cited by 8
FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells
Ishikawa, C., & Mori, N. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01196-1 · Cited by 8
Li, J., Ma, Y., Paquette, J. K., Richards, A. C., Mulvey, M. A., Zachary, J. F., Teuscher, C., & Weis, J. J. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010365 · Cited by 8
A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia
Zhang, L., Wu, M., Guo, W., Zhu, S., Li, S., Lv, S., Li, Y., Liu, L., Xing, Y., Huang, C., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115358 · Cited by 8
The ZBTB family in cardiac development and diseases
Xiang, X., Mao, J., Tang, D., Huang, H., & Tang, H. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152026 · Cited by 7
Radiomic features define risk and are linked to DNA methylation attributes in primary CNS lymphoma
Nenning, K., Gesperger, J., Furtner, J., Nemc, A., Roetzer-Pejrimovsky, T., Choi, S. W., Mitter, C., Leber, S. L., Hofmanninger, J., Klughammer, J., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad136 · Cited by 7
Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review)
Zhu, Z., Li, T., Zhang, X., Zhang, Z., Zhu, D., Lin, P., Tu, S., & Ren, W. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4917 · Cited by 7
Zhang, M., Gao, F., Zhao, Y.-W., Ni, B., Huang, H., & Hou, J. (2021) · Hematology · doi:10.1080/16078454.2021.2011546 · Cited by 7
Structural basis of Apt48 inhibition of the BCL6 BTB domain
Zacharchenko, T., Kalverda, A. P., & Wright, S. C. (2021) · Structure · doi:10.1016/j.str.2021.10.010 · Cited by 7
Kikuchi, H., Higuchi, T., Hashida, Y., Taniguchi, A., Kamioka, M., Taguchi, T., Yokoyama, A., Murakami, I., Fujieda, M., & Daibata, M. (2018) · Oncotarget · doi:10.18632/oncotarget.26060 · Cited by 7
Type 1 Diabetes Depends on CD4-Driven Expression of the Transcriptional Repressor Bcl6
McNitt, D. H., Williams, J. M., Santitoro, J. G., Kim, J., Thomas, J. W., & Bonami, R. H. (2024) · Diabetes · doi:10.2337/db23-0709 · Cited by 5
Chung, C. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219895079 · Cited by 6
Xing, Y., Tan, C., Liu, Z., Liu, Y., Liu, S., Wang, G., & Zhong, Y. (2025) · Journal of Natural Medicines · doi:10.1007/s11418-024-01873-4 · Cited by 5
Xia, Y., Jin, S., & Wu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1140703 · Cited by 5
Jia, K., Zhang, D., Wang, Y., Liu, Y., Kong, X., Yang, Q., Chen, H., Xie, C.-J., & Wang, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216470 · Cited by 4
Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research
Paximadis, M., Patrigeon, S. P., Rajasuriar, R., Tatoud, R., Scully, E. P., & Arbuthnot, P. B. (2019) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30027-3 · Cited by 4
B-cell lymphoma 6 in breast cancer: molecular mechanisms and clinical significance
Louwen, F., Ritter, A., Kreis, N., Hoock, S. C., Solbach, C., & Yuan, J. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2521319 · Cited by 4
Dutta, R. P., Lee, H., Leshchenko, V. V., Shukla, R. P., Yan, F., Liu, Y., Kanıskan, H. Ü., Qiu, X., Jin, J. J., Alinari, L., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016801 · Cited by 3
BCL6 is a context-dependent mediator of the glioblastoma response to irradiation therapy
Tribe, A. K. W., Peng, L., Teesdale‐Spittle, P. H., & McConnell, M. J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131782 · Cited by 3
3D in vitro microvascular model-based lymphoma model
Mannino, R. G., Pradhan, P., Roy, K., & Lam, W. A. (2018) · Methods in cell biology · doi:10.1016/bs.mcb.2018.05.007 · Cited by 3
Xing, Y., Guo, W., Wu, M., Xie, J., Huang, D., Hu, P., Zhou, M., Zhang, L., Zhang, Q., Wang, P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-820765/v1 · Cited by 3
The F-box E3 ligase protein FBXO11 regulates EBNA3C-associated degradation of BCL6
Sun, K., Bose, D., Singh, R. K., Pei, Y., & Robertson, E. S. (2024) · Journal of Virology · doi:10.1128/jvi.00548-24 · Cited by 2
Wen, S., Su, X., Guo, J., Ou, Z., Wang, L., Yue, Z., Zhao, J., Ran, L., Hu, J., Wang, Y., et al. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101505 · Cited by 2
How CBX proteins regulate normal and leukemic blood cells
de Groot, A. P., & de Haan, G. (2024) · FEBS Letters · doi:10.1002/1873-3468.14839 · Cited by 4
A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Xing, Y., Guo, W., Wu, M., Xie, J., Huang, D., Hu, P., Zhou, M., Zhang, L., Zhong, Y., Liu, M., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0830 · Cited by 2
Li, Y., Xing, Y., Huang, D., Xie, J., Peng, Y., Yi, Z., & Chen, Y. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2561541 · Cited by 2
Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia
Xiao, Y., Deng, F., Luo, Y., & Wang, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36640 · Cited by 1
Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects
Liu, R., Zhang, Z., Zhou, C., Wang, B., Zhang, M., Sun, Y., Yao, Y., Zhang, Y., He, Y., Yu, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1558845 · Cited by 1
Targeting RAB7 in human B lymphoma by a small molecule inhibitor arrests tumor cell growth
Fernandez, M., Wang, R., Wang, J., Wu, S., Holder, K. N., Nazarullah, A. N., Aguiar, R. C. T., Xu-Monette, Z. Y., Young, K. H., Yan, H. M., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1616519 · Cited by 1
BCL6 inhibition: a promising approach to prevent germinal center-driven allo-immune responses
Kraaijeveld, R., Hesselink, D. A., Steines, L., Heidt, S., & Baan, C. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1667185 · Cited by 2
Design synthesis and biological evaluation of novel BCL6/GSPT1 degrader as anti-DLBCL agent
Hu, R., Hu, X.-T., Yang, Y.-Y., Du, L., LAN, X., Luo, P., Li, C.-H., Luo-Ting., Y. U., & Wang, N. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118567 · Cited by 1
Discovery of pyrrolopyrimidinone inhibitors of the BCL6-SMRT corepressor interaction
Watson, I. D. G., Morin, J. A., Subramanian, P. R., Chau, A. M., Prakesch, M. A., Wilson, B. J., Morshed, M. M., Joseph, B. B., Uehling, D., Poda, G. I., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118575 · Cited by 1
Acevedo, A. F., Mack, J. J., & Valenzuela, N. M. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.07.026 · Cited by 1
Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy
Fuchs, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.15001-7 · Cited by 1
Signaling input from divergent pathways subverts malignant B-cell transformationPreprint
Chan, L. N., Murakami, M. A., Robinson, M. E., Caeser, R., Sadras, T., Lee, J. W., Cosgun, K. N., Kume, K., Khairnar, V., Xiao, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.12.989749 · Cited by 1
Self-citationThe DNA binding protein BCL6 regulates NFκB-controlled endothelial inflammatory gene expressionPreprint
Acevedo, A. F., Mack, J. J., & Valenzuela, N. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.03.514942 · Cited by 1
Gothwal, S. K., & Barlow, J. H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.19.628635 · Cited by 1
Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment
Hasan, M. K. (2017) · Biomedical Sciences · doi:10.11648/j.bs.20170302.12
DNA and Histone Methylation in Hematopoietic Malignancy
Kawabata, K. C., & Kitamura, T. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_14
The Influence of BCL6 on the WNT Pathway in Glioblastoma Therapy Resistance
Gordon-Schneider, R. (2018) · doi:10.26686/wgtn.17136140.v1
Anticancer innovative therapy: Highlights from the ninth annual meeting
Volpari, T., Santis, F. D., Bracken, A. P., Pupa, S. M., Buschbeck, M., Wegner, A., Cosimo, S. D., Lisanti, M. P., Dotti, G., Massaia, M., et al. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.12.002
Follicular lymphoma: Biology update
Nadel, B. (2019) · Hématologie · doi:10.1684/hma.2019.1489
Najari, A., Aminiyanfar, M., Mobasheri, M., & Sobati, T. (2021) · Research Square · doi:10.21203/rs.3.rs-220326/v1
Ribosome changes elicit non-canonical translation for chemosurvival in G0 leukemic cellsPreprint
Datta, C., Truesdell, S., Bukhari, S., Ngue, H., Buchanan, B., Wu, K., Tonqueze, O. L., Lee, S., Granovetter, M., Boukhali, M., et al. (2021) · bioRxiv · doi:10.1101/2021.12.07.471635
The Role of BCL6 in Glioblastoma
Jones, N. M. (2018) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17072567
The Influence of BCL6 on the WNT Pathway in Glioblastoma Therapy Resistance
Gordon-Schneider, R. (2018) · doi:10.26686/wgtn.17136140
BCL6 regulates the endothelial pro-immunogenic phenotype relevant to organ transplant rejectionPreprint
Acevedo, A. F., & Valenzuela, N. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.03.514941
BCL6 is a context-dependent mediator of the glioblastoma therapy response
Tribe, A. K. W. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.21937850
Fernando, T. M., Marullo, R., Gresely, B. P., Phillip, J. M., Yang, S. N., Lundell-Smith, G., Torregroza, I., Ahn, H., Evans, T., Győrffy, B., et al. (2023) · doi:10.1158/2159-8290.22532999
Self-citationFernando, T. M., Marullo, R., Gresely, B. P., Phillip, J. M., Yang, S. N., Lundell-Smith, G., Torregroza, I., Ahn, H., Evans, T., Győrffy, B., et al. (2023) · doi:10.1158/2159-8290.22532999.v1
Self-citationXing, Y., Guo, W., Wu, M. Y., Xie, J., Huang, D., Hu, P., Zhou, M., Zhang, Q., Wang, P., Wang, X., et al. (2024) · doi:10.22541/au.170667314.42007148/v1
Epidermal loss of Bcl6 exacerbates MC903-induced atopic dermatitis-like skin inflammation
Kanemaru, K., Nagasawa, K., Kunugi, Y., Tanaka, A., Ikeoku, S., Tai, Y., Harada, Y., & Nakamura, Y. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149745
Cai, Z., You, S., Liu, Z., Song, P., Zhao, F., An, J., Ding, Y., He, B., & Zou, M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06597-7
Gothwal, S. K., Oichai, K., & Barlow, J. H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.13.643172
Small Molecule Inhibitors Targeting Protein–Protein Interactions in the BCL Protein
Zhu, W., He, Y., Chen, G., & Zhu, D. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch12
Mamai, A., Morshed, M. M., Prakesch, M. A., Poda, G. I., Pandiaraju, S., Chau, A. M., Watson, I. D. G., Joseph, B., Wilson, B., Morin, J. A., et al. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130471
Protein-protein interaction inhibitors in cancer
Hardcastle, I. R., Goujon-Ricci, J., & Thompson, W. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00067-4
Ruggiu, M. (2023) · theses.fr (ABES) · doi:10.70675/de84e089z4e46z475dz8d12z25950ab6f427
Mouse models of B cell lymphomas on the basis of genetic features
Yuan, M., & Wang, J. Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1870989
Oncogenic Role of BCL6 Rearrangement: A Focus on Follicular and Marginal Zone Lymphomas
Pâris, L., Chassagne-Clement, C., Bachy, E., Ghesquières, H., Mauduit, C., Pissaloux, D., Trécourt, A., Laurent, C., Beillard, E. J., Traverse‐Glehen, A., et al. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101055
Gothwal, S. K., Oichai, K., Kim, H., Myung, K., & Barlow, J. H. (2026) · Hematological Oncology · doi:10.1002/hon.70227
BindingDB Entry 50007681: Achieving
BindingDB (2021) · UC San Diego · doi:10.7270/q2df6vk2
BindingDB (2023) · UC San Diego · doi:10.7270/q23b6472
BindingDB Entry 50019677: Discovery of an
BindingDB (2024) · UC San Diego · doi:10.7270/q2ms3z53
BindingDB (2023) · UC San Diego · doi:10.7270/q2r21585
BindingDB Entry 50008540: Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
BindingDB (2021) · UC San Diego · doi:10.7270/q2gf0xw8
BindingDB Entry 50002640: A genetically selected cyclic peptide inhibitor of BCL6 homodimerization.
BindingDB (2020) · UC San Diego · doi:10.7270/q2sn0cnc
Metadata
- Authors
- Cardenas, M. G., Yu, W., Beguelin, W., Teater, M. R., Geng, H., Goldstein, R. L., Oswald, E., Hatzi, K., Yang, S.-N., Cohen, J., Shaknovich, R., Vanommeslaeghe, K., Cheng, H., Liang, D., Cho, H. J., Abbott, J., Tam, W., Du, W., Leonard, J. P., Elemento, O., Cerchietti, L., Cierpicki, T., Xue, F., MacKerell, A. D., & Melnick, A. M.
- Affiliations
- University of Maryland, Baltimore (US)
- University of California, San Francisco (US)
- Weill Cornell Medicine (US)
- University of Michigan (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-02
- Volume
- 126
- Issue
- 9
- Pages
- 3351-3362
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5004937
- OpenAlex
- W2505733981
- Cited by
- 176
- References
- 40
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 19 · 2023: 14 · 2022: 25 · 2021: 16 · 2020: 21 · 2019: 18 · 2018: 20 · 2017: 16 · 2016: 5
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Samuel Waxman Cancer Research Foundation
- Leukemia and Lymphoma Society
- Weill Cornell Medical College
- National Cancer Institute (R01CA194547)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- BCL6, small molecule inhibitors, germinal center, chromosomal translocation, lymphoma treatment
- MeSH terms
- Animals, Antineoplastic Agents, Doxorubicin, Drug Screening Assays, Antitumor, Humans, Indoles, Ligands, Male, Neoplasm Transplantation, Magnetic Resonance Spectroscopy, Protein Binding, Translocation, Genetic, Drug Design, Gene Expression Regulation, Neoplastic, Lymphoma, Large B-Cell, Diffuse, Mice, SCID, Thiazolidinediones, Cell Line, Tumor, Mice, Proto-Oncogene Proteins c-bcl-6, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
